Genedx Holdings Stock Price Today
At the forefront of genetic testing, transforming the diagnosis and treatment of rare disorders through revolutionary genomic analysis stands GeneDx.
The company has decoded over 700,000 clinical exomes and genomes since its inception in 2000. Sometimes as quick as five days, their turnaround time is world-renowned.
Owing to their recent net profit of 1.4 Million USD investors have turned their attention to GeneDx Holdings stock price prediction (WGS Forecast) 2024,2025,2030,2040,2050 as a tremendous investment opportunity.
GeneDx has become an essential partner in neonatal care, offering life-changing insights through advanced technologies like whole exome sequencing (WES) and whole genome sequencing (WGS). Their seminal work in genomic newborn screening makes them the most experienced lab in this space across the U.S.
Also Read:-Azek Stock Price Prediction Today- (Forecast) 2024, 2025, 2030, 2040, 2050
GeneDx business model
GeneDx is a publicly traded genetic testing company that aims to provide unparalleled diagnostic services for patients (primarily children) suffering from rare or ultra-rare disorders.
Their core business model involves conducting exome and genome sequencing tests to analyze a patient’s genetic material and identify the potential of a new disease early on. GeneDx earns money through a range of sources. Their reputation differentiates them in the genetic testing market and they are actively working with medical staff, scientists, and patients to develop new tests for conditions that are not available in other labs.
With data from over 700,000 exomes and genome sequenced, they leverage one of the world’s largest rare disease data sets. This data paired with a tier state-of-the-art interpretation platform helps them in providing accurate diagnosis.
They also partner with healthcare providers who order tests and receive results. They also partner with biopharma companies to share their de-identified rare disease data set, aiding in drug discovery and clinical trial enrollment.
Their reputation and accurate testing have earned them $76.6 million USD in the third quarter of 2024. This shows a spectacular 77% year-over-year growth. This revenue is accumulated by performing genetic tests in over 55 countries.
History of GeneDx
To better understand GeneDx Holdings stock price prediction (WGS Forecast) 2024,2025,2030,2040,2050 you first need to understand how it began.
GenDx began as the dream project of two scientists from the National Institute of Health (NIH); Dr Sherri Bale and Dr John Compton in 2000. Bale and Compton started this company with the objective of providing clinical diagnostic services to patients with rare and ultra-rare disorders. At the time of its inception, there was no commercial testing available for these disorders.
GeneDx began operating out of the Technology Development Center incubator in Maryland. In 2006, GeneDx was acquired by BioReference Laboratories for approximately $17 million. GeneDx operated as a BioReference Laboratories subsidiary under Bale and Compton’s leadership. Bale retired in 2016 and Compton retired in 2013
In 2007, they launched their first array CGH (Comparative Genomic Hybridization) test, also called microarray analysis. Microarray analysis was a great option to obtain high-resolution, genome-wide screening of segmental genomic copy number variations. By 2018, GeneDx announced that it had performed clinical Exome Sequencing on more than 100,000 individuals.
In January 2022, GeneDx was acquired by Sema4, an AI-driven genomic and clinical data intelligence platform company.
GeneDx achieved profitability in the third quarter of 2024, with an adjusted net income of $1.2 million. Today the company is based out of its headquarters in Stamford, Connecticut. GeneDx is a leader in genomic newborn screening as well and has conducted more genomic newborn screenings than any other lab in the United States.
Future Planning of GeneDx
Since they turned profitable, the GeneDx stock prediction for 2024, 2025, 2030, 2040, 2050 has taken a drastic turn recommending people to invest in it as soon as possible.
The current price of GeneDx stock is 79.43 USD. However, analysts have predicted exponential growth in their future owing to their recent partnerships and several new initiatives. GeneDx is developing a clinically actionable and scalable genomic newborn screening which is predicted to drive future growth.
They are also leveraging their partnerships to enhance growth. They recently partnered with Komodo Health to provide biopharma companies with access to genetic insights that could inform drug development and clinical trials. Due to the ever-growing number of families eligible for their services and their continuously growing respect and reliability amongst their existing clients, their growth is predicted to be sustainable and healthy over the upcoming decades.
Competitors of GeneDx
Although their database is unparalleled and experience unrivalled, GeneDx stock prediction still operates in a competitive landscape, facing challenges from a diverse range of companies which specialise in healthcare, genetic testing and precision medicine.
Competitors like Natera, Invitae, and Ambry Genetics lead the industry with comprehensive offerings in genetic analysis.
Natera excels in cell-free DNA testing across oncology, women’s health, and organ health, providing it a significant edge in expanding markets such as prenatal diagnostics and cancer treatment.
Invitae combines advanced genetic testing with actionable insights, positioning itself as a leader in improving patient care for hereditary conditions and rare diseases.
Ambry Genetics is renowned for its hereditary cancer panels and exome sequencing, a key focus area for GeneDx, creating direct competition.
Other competitors, such as Guardant Health, are making use of precision oncology solutions and focus on liquid biopsies that allow non-invasive cancer detection. Companies like Flatiron Health and Tempus further increase the competitive pressure by integrating AI and real-world data to further streamline patient care.
GeneDx competes with these players by leveraging its expertise in Exome and Genome sequencing and incredibly massive datasets making people confident about GeneDx stock predictions. However, its competitors are using AI integration to increase their response speed and threaten GeneDx’s share of the market.
GeneDx Price Prediction December 2024
| Month | $Monthly Open | $Monthly low | $Monthly high | $Monthly close | Total% |
| Dec. 2024 | 78.39 | 78.82 | 81.98 | 81.72 | 4.25 |
GeneDx Stock Price Prediction for December 2024: The monthly open is 78.39, the Monthly low is 78.82, the monthly high is 81.98 and the monthly close price is 81.72. At the dollar end, the change for December is 4.25%.
GeneDx Price Prediction: January to June 2025
| Month | $Monthly Open | $Monthly low | $Monthly high | $Monthly close | Total% |
| Jan. 2025 | 81.72 | 86.57 | 123.74 | 121.55 | 48.74 |
| Fab. 2025 | 121.55 | 123.38 | 186.14 | 184.81 | 52.08 |
| Mar 2025 | 184.81 | 187.45 | 271.23 | 263.16 | 42.39 |
| Apr 2025 | 263.16 | 267.47 | 376.31 | 369.24 | 40.31 |
| May 2025 | 372.42 | 378.06 | 562.24 | 543.84 | 46.03 |
| Jun 2025 | 543.84 | 564.51 | 788.74 | 775.62 | 42.62 |
GeneDx stock price Prediction for January 2025: The monthly open is 81.72, the Monthly low is 86.57, the monthly high is 123.74, and the monthly close price is 121.55 At the dollar end, the change for January is 48.74%.
GeneDx stock price Prediction for February 2025: The monthly open is 121.55, the Monthly low is 123.38, the monthly high is 186.14, and the monthly close price is 184.81. At the dollar end, the change for February is 52.08%.
GeneDx stock price Prediction for March 2025: The monthly open is 184.81, the Monthly low is 187.45, the monthly high is 271.23, and the monthly close price is 263.16. At the dollar end, the change for March is 42.39%.
GeneDx stock price Prediction for April 2025: The monthly open is 263.16, the Monthly low is 267.47, the monthly high is 376.31, and the monthly close price is 369.24. At the dollar end, the change for April is 40.31%.
GeneDx stock price Prediction for May 2025: The monthly open is 372.42, the Monthly low is 378.06, the monthly high is 562.24, and the monthly close price is 543.84. At the dollar end, the change for May is 46.03%.
GeneDx stock price Prediction for Jun 2025: The monthly open is 543.84, the Monthly low is 564.51, the monthly high is 788.74, and the monthly close price is 775.62. At the dollar end, the change for Jun is 42.62%.
Azek Stock Price Prediction: July to December 2025
| Month | $Monthly low | $Monthly high | $Monthly high | $Monthly close | Total% |
| Jul 2025 | 775.62 | 801.03 | 1,262.41 | 1,150.78 | 44.99 |
| Aug. 2025 | 1,150.78 | 1,265.06 | 1,714.56 | 1,655.05 | 43.82 |
| Sept. 2025 | 1,655.05 | 1,687.09 | 2,358.12 | 2,287.94 | 38.24 |
| Oct. 2025 | 2,287.94 | 2,365.45 | 3,056.30 | 2,969.28 | 29.78 |
| Nov.2025 | 2,969.28 | 3,049.07 | 4,056.52 | 3,906.08 | 31.55 |
| Dec.2025 | 3,906.08 | 4,105.80 | 5,368.47 | 5,275.55 | 35.06 |
GeneDx stock price Prediction for July 2025: The monthly open is 775.62, the Monthly low is 801.03, the monthly high is 1,262.41, and the monthly close price is 1,150.78. At the dollar end, the change for July is 44.99%
GeneDx stock price Prediction for August 2025: The monthly open is 1,150.78, the Monthly low is 1,265.06, the monthly high is 1,714.56, and the monthly close price is 1,655.05. At the dollar end, the change for August is 43.82%.
GeneDx stock price Prediction for September 2025: The monthly open is 1,655.05, the Monthly low is 1,687.09, the monthly high is 2,358.12, and the monthly close price is 2,287.94. At the dollar end, the change for September is 38.24%.
GeneDx stock price Prediction for October 2025: The monthly open is 2,287.94, the Monthly low is 2,365.45, the monthly high is 3,056.30, and the monthly close price is 2,969.28. At the dollar end, the change for October is 29.78%.
GeneDx stock price Prediction for November 2025: The monthly open is 2,969.28, the Monthly low is 3,049.07, the monthly high is 4,056.52, and the monthly close price is 3,906.08, At the dollar end, the change for November is 31.55%
GeneDx stock price Prediction for December 2025: The monthly open is 3,906.08, the Monthly low is 4,105.80, the monthly high is 5,368.47, and the monthly close price is 5,275.55. At the dollar end, the change for December is 35.06%.
GeneDx Stock Price Prediction 2030
| Year | $Annual Open | $Annual low | $Annual high | $Annual close | Total% |
| 2030 | 5.275M | 6.475M | 19.147M | 18.071M | 242.56 |
GeneDx Stock Price Prediction for 2030: The annual open is 5.275M, the annual low is 6.475M, the annual high is 19.147M, and the annual close price is 18.071M. At the dollar end, the change for 2030 is 242.56%
GeneDx Stock Price Prediction 2040
| Year | $Annual Open | $Annual low | $Annual high | $Annual close | Total% |
| 2040 | 45.27M | 48.45M | 65.87M | 63.342M | 39.92 |
GeneDx Stock Price Prediction for 2040: The annual open is 45.27M, the annual low is 48.45M, the annual high is 65.87M, and the annual close price is 63.342M. At the dollar end, the change for 2040 is 39.92%
GeneDx Stock Price Prediction 2050
| Year | $Annual Open | $Annual low | $Annual high | $Annual close | Total% |
| 2050 | 114.37M | 117.45M | 163.45M | 160.43M | 40.28 |
GeneDx Stock Price Prediction for 2040: The annual open is 114.37M, the annual low is 117.45M, the annual high is 163.45M, and the annual close price is 160.43M. At the dollar end, the change for 2040 is 40.28%
Conclusion
In conclusion, it is the perfect time to use your savings to invest in GeneDx according to stock predictions if you haven’t already done so. Their track record and experiences make the GeneDx stock prediction for 2024, 2025, 2030, 2040 and 2050 a piece of cake for everyone to understand.
They have succeeded in gaining client’s trust over decades and have successfully established themselves in over 50 countries. Their frequent partnership with enterprises has helped them reach a wide audience and decreased their response time to merely 5 days. Their Genome and Exome analytical technology is one of the best ever invented and when supplemented with their future endeavours into newborn screening, their growth is all but certain.
Considering the future predictions for their stock, its current value of 79.43 USD is a very minimal price to pay for investing in such a large company.
FAQ’s about GeneDx stock
Q1. Should I buy GeneDx stock?
Considering the current valuation of the stock – 79USd it becomes a very good investment opportunity to invest your savings. Every GeneDx Stock prediction says that It is expected to grow exponentially over the coming years and if you have the patience to hold the stock for a few years it could appreciate almost 10 times in value.
Q2. What is the name of GeneDx stock?
Their stock is listed under GeneDx Holdings Corp (Wgs)
Q3. What is GeneDx stock prediction for 2025?
Owing to their recent profitability and massive year-on-year growth rate of 77% analysts predict that the WGS stock price will grow to around 80.83 – 95 USD.
Q4.Is GeneDx profitable?
GeneDx accumulated a net income of 1.2 Million USD in Q3 of 2024. They have delivered a spectacular 77% growth in exome and genome revenues. “It is a significant milestone Q4. in the company’s history,” said Katherine Stueland, CEO of GeneDx
Q5.Who is the CEO of GeneDx?
Katherine Stueland who has dedicated her career to transforming healthcare through leadership at patient-centric businesses is their current CEO.
Q6. Who bought GeneDx?
Sema4 acquired GeneDx in April 2022 from Opko Health for $623 Million. Their company was previously acquired by BioReference Laboratories for approximately $17 million in 2006.
Disclaimer:–
The stock price predictions provided herein are based on historical data, current market trends, and analysis. However, past performance does not guarantee future results. Stock markets are inherently volatile and subject to numerous economic, political, and market factors that can cause rapid and unpredictable fluctuations in stock prices. The information provided is for educational and informational purposes only and should not be construed as financial advice. It is strongly recommended that you consult with a qualified financial advisor before making any investment decisions. Invest responsibly and consider your individual financial situation, risk tolerance, and investment objectives before acting on any information provided.
Also Read:-MicroStrategy Stock Price Prediction & Today (MSTR) Forecast 2024, 2025,2030,2040,2050
